IL6 and COVID-19: The REMAP-CAP trial experimented with the use of tocilizumab and another IL-6 inhibitor (sarilimumab) in critically ill COVID-19 patients: patients treated with both drugs showed better outcomes, including survival, compared to standard care [75].